Concepts (202)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Ovarian Neoplasms | 26 | 2024 | 772 | 4.090 |
Why?
|
| Tumor Microenvironment | 12 | 2024 | 476 | 1.820 |
Why?
|
| Neoplasm Metastasis | 11 | 2019 | 1066 | 1.280 |
Why?
|
| Peritoneal Cavity | 2 | 2021 | 21 | 1.260 |
Why?
|
| High-Throughput Screening Assays | 3 | 2019 | 58 | 1.240 |
Why?
|
| Epithelial Cells | 5 | 2015 | 693 | 0.990 |
Why?
|
| Omentum | 7 | 2018 | 74 | 0.970 |
Why?
|
| Extracellular Matrix | 4 | 2015 | 245 | 0.910 |
Why?
|
| Peritoneal Neoplasms | 6 | 2023 | 181 | 0.830 |
Why?
|
| Epithelium | 4 | 2021 | 323 | 0.790 |
Why?
|
| Stromal Cells | 2 | 2019 | 151 | 0.760 |
Why?
|
| Fibronectins | 2 | 2014 | 101 | 0.740 |
Why?
|
| Cell Adhesion | 11 | 2017 | 426 | 0.710 |
Why?
|
| Neoplasms, Glandular and Epithelial | 3 | 2015 | 75 | 0.700 |
Why?
|
| Inhibins | 4 | 2005 | 37 | 0.680 |
Why?
|
| Mice, Nude | 12 | 2019 | 816 | 0.660 |
Why?
|
| Cell Line, Tumor | 15 | 2024 | 2588 | 0.630 |
Why?
|
| Matrix Metalloproteinase 2 | 2 | 2009 | 48 | 0.620 |
Why?
|
| Microfilament Proteins | 1 | 2019 | 212 | 0.570 |
Why?
|
| Mice | 22 | 2024 | 11863 | 0.560 |
Why?
|
| Ovarian Follicle | 4 | 2005 | 72 | 0.550 |
Why?
|
| Neoplasm Invasiveness | 9 | 2015 | 569 | 0.540 |
Why?
|
| Organ Culture Techniques | 1 | 2015 | 135 | 0.510 |
Why?
|
| Carrier Proteins | 1 | 2019 | 679 | 0.500 |
Why?
|
| Coculture Techniques | 7 | 2018 | 176 | 0.480 |
Why?
|
| Xenograft Model Antitumor Assays | 6 | 2019 | 486 | 0.460 |
Why?
|
| Animals | 29 | 2024 | 27543 | 0.460 |
Why?
|
| Fibroblasts | 4 | 2015 | 759 | 0.450 |
Why?
|
| Spheroids, Cellular | 2 | 2017 | 31 | 0.410 |
Why?
|
| Female | 31 | 2024 | 46635 | 0.400 |
Why?
|
| Receptors, Urokinase Plasminogen Activator | 2 | 2013 | 21 | 0.390 |
Why?
|
| Gene Expression Regulation, Neoplastic | 4 | 2024 | 1284 | 0.390 |
Why?
|
| Photoperiod | 2 | 2002 | 73 | 0.380 |
Why?
|
| Antineoplastic Agents | 5 | 2017 | 2331 | 0.380 |
Why?
|
| Neoplastic Stem Cells | 2 | 2024 | 162 | 0.330 |
Why?
|
| RNA, Small Interfering | 4 | 2019 | 557 | 0.330 |
Why?
|
| Cell Movement | 4 | 2019 | 787 | 0.320 |
Why?
|
| Tissue Culture Techniques | 1 | 2009 | 82 | 0.310 |
Why?
|
| Cancer-Associated Fibroblasts | 2 | 2019 | 37 | 0.310 |
Why?
|
| Carcinogenesis | 2 | 2021 | 216 | 0.310 |
Why?
|
| Vitronectin | 1 | 2008 | 6 | 0.310 |
Why?
|
| Cell Culture Techniques | 4 | 2017 | 195 | 0.300 |
Why?
|
| Cell Proliferation | 6 | 2021 | 1670 | 0.290 |
Why?
|
| Humans | 32 | 2024 | 90039 | 0.270 |
Why?
|
| Models, Biological | 5 | 2015 | 1766 | 0.260 |
Why?
|
| Tumor Cells, Cultured | 5 | 2019 | 1048 | 0.260 |
Why?
|
| Estrus | 1 | 2005 | 43 | 0.260 |
Why?
|
| Carcinoma | 1 | 2009 | 438 | 0.250 |
Why?
|
| Forkhead Box Protein M1 | 1 | 2024 | 16 | 0.230 |
Why?
|
| Adipocytes | 2 | 2018 | 163 | 0.220 |
Why?
|
| Gonadotropins, Equine | 1 | 2002 | 12 | 0.210 |
Why?
|
| Inhibin-beta Subunits | 1 | 2002 | 4 | 0.210 |
Why?
|
| Leukocyte Elastase | 1 | 2021 | 8 | 0.190 |
Why?
|
| Neutrophils | 2 | 2021 | 312 | 0.180 |
Why?
|
| Vascular Endothelial Growth Factors | 1 | 2019 | 56 | 0.170 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2019 | 606 | 0.160 |
Why?
|
| Liposomes | 2 | 2016 | 93 | 0.160 |
Why?
|
| Extracellular Traps | 1 | 2018 | 12 | 0.160 |
Why?
|
| Matrix Metalloproteinase Inhibitors | 2 | 2009 | 13 | 0.160 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2019 | 156 | 0.160 |
Why?
|
| Small Molecule Libraries | 1 | 2019 | 65 | 0.150 |
Why?
|
| Signal Transduction | 5 | 2024 | 3404 | 0.150 |
Why?
|
| Bevacizumab | 1 | 2019 | 268 | 0.150 |
Why?
|
| Glycogen | 1 | 2018 | 59 | 0.150 |
Why?
|
| CD36 Antigens | 1 | 2018 | 13 | 0.150 |
Why?
|
| Gene Knockdown Techniques | 1 | 2019 | 247 | 0.150 |
Why?
|
| Metformin | 1 | 2019 | 124 | 0.150 |
Why?
|
| Cell Growth Processes | 2 | 2015 | 85 | 0.150 |
Why?
|
| Matrix Metalloproteinase 9 | 2 | 2008 | 86 | 0.150 |
Why?
|
| Neovascularization, Pathologic | 1 | 2019 | 354 | 0.140 |
Why?
|
| Fatty Acids, Unsaturated | 1 | 2017 | 28 | 0.140 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2019 | 204 | 0.140 |
Why?
|
| Neoplasms, Experimental | 1 | 2018 | 269 | 0.140 |
Why?
|
| Models, Animal | 2 | 2009 | 277 | 0.130 |
Why?
|
| Antibodies, Monoclonal | 2 | 2013 | 1396 | 0.130 |
Why?
|
| Cells, Cultured | 3 | 2018 | 2887 | 0.130 |
Why?
|
| Escin | 1 | 2015 | 2 | 0.120 |
Why?
|
| Prochlorperazine | 1 | 2015 | 2 | 0.120 |
Why?
|
| Tomatine | 1 | 2015 | 2 | 0.120 |
Why?
|
| Cantharidin | 1 | 2015 | 3 | 0.120 |
Why?
|
| Biguanides | 1 | 2015 | 6 | 0.120 |
Why?
|
| Benzophenanthridines | 1 | 2015 | 23 | 0.120 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2015 | 64 | 0.120 |
Why?
|
| Primary Cell Culture | 1 | 2015 | 77 | 0.120 |
Why?
|
| Protease Inhibitors | 2 | 2021 | 72 | 0.120 |
Why?
|
| Isoquinolines | 1 | 2015 | 73 | 0.120 |
Why?
|
| Paclitaxel | 1 | 2016 | 474 | 0.120 |
Why?
|
| Integrins | 1 | 2014 | 78 | 0.120 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2014 | 89 | 0.110 |
Why?
|
| Urokinase-Type Plasminogen Activator | 1 | 2013 | 51 | 0.110 |
Why?
|
| Neoplasms | 2 | 2021 | 3067 | 0.110 |
Why?
|
| Phodopus | 2 | 2002 | 59 | 0.100 |
Why?
|
| Endothelial Cells | 2 | 2019 | 464 | 0.100 |
Why?
|
| Cricetinae | 2 | 2002 | 558 | 0.100 |
Why?
|
| Cell Survival | 2 | 2016 | 983 | 0.090 |
Why?
|
| Apoptosis | 3 | 2016 | 1718 | 0.090 |
Why?
|
| Integrin alphaVbeta3 | 1 | 2009 | 17 | 0.080 |
Why?
|
| Integrin alpha5 | 1 | 2008 | 6 | 0.080 |
Why?
|
| Staining and Labeling | 1 | 2009 | 169 | 0.080 |
Why?
|
| Cattle | 1 | 2009 | 378 | 0.080 |
Why?
|
| Abdominal Cavity | 1 | 2008 | 18 | 0.080 |
Why?
|
| Integrin beta1 | 1 | 2007 | 33 | 0.070 |
Why?
|
| Procollagen-Proline Dioxygenase | 1 | 2007 | 11 | 0.070 |
Why?
|
| Microscopy, Phase-Contrast | 1 | 2007 | 31 | 0.070 |
Why?
|
| CA-125 Antigen | 1 | 2007 | 22 | 0.070 |
Why?
|
| Keratins | 1 | 2007 | 63 | 0.070 |
Why?
|
| Thrombin | 1 | 2007 | 61 | 0.070 |
Why?
|
| Vimentin | 1 | 2007 | 46 | 0.070 |
Why?
|
| Transplantation, Heterologous | 1 | 2009 | 368 | 0.070 |
Why?
|
| Disease Progression | 3 | 2019 | 1469 | 0.070 |
Why?
|
| Cadherins | 1 | 2008 | 163 | 0.070 |
Why?
|
| Antibodies | 1 | 2008 | 353 | 0.070 |
Why?
|
| beta Catenin | 1 | 2007 | 267 | 0.060 |
Why?
|
| Mice, Knockout | 2 | 2008 | 2016 | 0.060 |
Why?
|
| Neoplasm Proteins | 1 | 2009 | 538 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2007 | 200 | 0.060 |
Why?
|
| Receptors, FSH | 1 | 2004 | 7 | 0.060 |
Why?
|
| Focal Adhesion Kinase 1 | 1 | 2024 | 33 | 0.060 |
Why?
|
| Follicle Stimulating Hormone | 1 | 2004 | 147 | 0.060 |
Why?
|
| Phthalazines | 1 | 2024 | 46 | 0.060 |
Why?
|
| Survival Rate | 1 | 2008 | 1901 | 0.060 |
Why?
|
| MAP Kinase Signaling System | 2 | 2018 | 198 | 0.050 |
Why?
|
| Transcription, Genetic | 1 | 2008 | 1158 | 0.050 |
Why?
|
| Immunohistochemistry | 1 | 2007 | 1801 | 0.050 |
Why?
|
| Amino Acid Sequence | 2 | 2007 | 2064 | 0.050 |
Why?
|
| Ascites | 1 | 2023 | 56 | 0.050 |
Why?
|
| Prognosis | 4 | 2016 | 3801 | 0.050 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2005 | 1237 | 0.050 |
Why?
|
| Piperazines | 1 | 2024 | 283 | 0.050 |
Why?
|
| In Situ Hybridization | 1 | 2002 | 313 | 0.050 |
Why?
|
| DNA, Complementary | 1 | 2002 | 391 | 0.050 |
Why?
|
| Eosinophil Cationic Protein | 1 | 2021 | 4 | 0.050 |
Why?
|
| Secretory Leukocyte Peptidase Inhibitor | 1 | 2021 | 5 | 0.050 |
Why?
|
| Pancreatic Elastase | 1 | 2021 | 15 | 0.050 |
Why?
|
| Trans-Activators | 1 | 2004 | 443 | 0.050 |
Why?
|
| Allosteric Regulation | 1 | 2021 | 67 | 0.050 |
Why?
|
| fas Receptor | 1 | 2021 | 77 | 0.050 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2016 | 855 | 0.050 |
Why?
|
| Protein Domains | 1 | 2021 | 136 | 0.040 |
Why?
|
| Proteolysis | 1 | 2021 | 114 | 0.040 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2002 | 885 | 0.040 |
Why?
|
| Protein Isoforms | 1 | 2021 | 278 | 0.040 |
Why?
|
| Succinate-CoA Ligases | 1 | 2019 | 3 | 0.040 |
Why?
|
| Prolyl Hydroxylases | 1 | 2019 | 4 | 0.040 |
Why?
|
| Cell Death | 1 | 2021 | 261 | 0.040 |
Why?
|
| Neoplasm Transplantation | 2 | 2011 | 397 | 0.040 |
Why?
|
| Swine | 1 | 2021 | 590 | 0.040 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 2019 | 67 | 0.040 |
Why?
|
| Rats | 1 | 2005 | 4048 | 0.040 |
Why?
|
| Hydrolases | 1 | 2018 | 30 | 0.040 |
Why?
|
| Histones | 1 | 2021 | 333 | 0.040 |
Why?
|
| Extracellular Vesicles | 1 | 2019 | 42 | 0.040 |
Why?
|
| Heparin | 1 | 2019 | 185 | 0.040 |
Why?
|
| Gene Expression | 2 | 2016 | 1309 | 0.040 |
Why?
|
| DNA-Binding Proteins | 1 | 2004 | 1243 | 0.040 |
Why?
|
| RNA | 1 | 2002 | 583 | 0.040 |
Why?
|
| Integrin alpha5beta1 | 2 | 2008 | 13 | 0.040 |
Why?
|
| Glycolysis | 1 | 2018 | 135 | 0.040 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2019 | 405 | 0.040 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2021 | 600 | 0.030 |
Why?
|
| Hypoglycemic Agents | 1 | 2019 | 352 | 0.030 |
Why?
|
| Multidrug Resistance-Associated Proteins | 1 | 2016 | 27 | 0.030 |
Why?
|
| Cell Cycle Checkpoints | 1 | 2016 | 67 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 1 | 2018 | 1091 | 0.030 |
Why?
|
| Up-Regulation | 1 | 2018 | 726 | 0.030 |
Why?
|
| Cell Cycle | 2 | 2009 | 508 | 0.030 |
Why?
|
| Arsenates | 1 | 2013 | 2 | 0.030 |
Why?
|
| Animals, Genetically Modified | 1 | 2013 | 183 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2019 | 3256 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2013 | 310 | 0.020 |
Why?
|
| Oxidative Stress | 1 | 2015 | 458 | 0.020 |
Why?
|
| Fatty Acid-Binding Proteins | 1 | 2011 | 25 | 0.020 |
Why?
|
| Polyethylene Glycols | 1 | 2013 | 360 | 0.020 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2013 | 450 | 0.020 |
Why?
|
| Lipid Metabolism | 1 | 2011 | 201 | 0.020 |
Why?
|
| Protein Binding | 1 | 2013 | 1492 | 0.020 |
Why?
|
| RNA, Messenger | 2 | 2007 | 2026 | 0.020 |
Why?
|
| Receptor, PAR-1 | 1 | 2007 | 2 | 0.020 |
Why?
|
| Aged, 80 and over | 2 | 2009 | 6790 | 0.020 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2007 | 268 | 0.020 |
Why?
|
| Osteosarcoma | 1 | 2007 | 161 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2008 | 793 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2013 | 2395 | 0.020 |
Why?
|
| Transfection | 1 | 2008 | 909 | 0.020 |
Why?
|
| Bone Neoplasms | 1 | 2007 | 321 | 0.020 |
Why?
|
| Follicular Atresia | 1 | 2004 | 2 | 0.010 |
Why?
|
| Cyclin D2 | 1 | 2004 | 19 | 0.010 |
Why?
|
| Cell Membrane | 1 | 2007 | 677 | 0.010 |
Why?
|
| Ovulation | 1 | 2004 | 68 | 0.010 |
Why?
|
| Smad3 Protein | 1 | 2004 | 25 | 0.010 |
Why?
|
| Cyclins | 1 | 2004 | 82 | 0.010 |
Why?
|
| Sequence Deletion | 1 | 2004 | 205 | 0.010 |
Why?
|
| Estradiol | 1 | 2004 | 250 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2004 | 194 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2007 | 3024 | 0.010 |
Why?
|
| Biomarkers | 1 | 2009 | 1778 | 0.010 |
Why?
|
| Down-Regulation | 1 | 2004 | 521 | 0.010 |
Why?
|
| Receptors, Estrogen | 1 | 2004 | 394 | 0.010 |
Why?
|
| Aged | 2 | 2009 | 19280 | 0.010 |
Why?
|
| Biomarkers, Tumor | 1 | 2008 | 1545 | 0.010 |
Why?
|
| Middle Aged | 2 | 2009 | 26191 | 0.010 |
Why?
|
| Adult | 2 | 2009 | 26856 | 0.010 |
Why?
|